The stock price of Replimune Group Inc (NASDAQ: REPL) has jumped by 9.63 compared to previous close of 7.99. Despite this, the company has seen a gain of 19.25% in its stock price over the last five trading days. globenewswire.com reported 2025-04-11 that WOBURN, Mass., April 11, 2025 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees.
Is It Worth Investing in Replimune Group Inc (NASDAQ: REPL) Right Now?
The 36-month beta value for REPL is at 0.75. Analysts have varying views on the stock, with 3 analysts rating it as a “buy,” 5 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for REPL is 61.80M, and currently, shorts hold a 15.49% of that float. The average trading volume for REPL on April 22, 2025 was 781.15K shares.
REPL’s Market Performance
REPL stock saw a decrease of 19.25% in the past week, with a monthly decline of -24.44% and a quarterly a decrease of -13.56%. The volatility ratio for the week is 8.46%, and the volatility levels for the last 30 days are 9.02% for Replimune Group Inc (REPL). The simple moving average for the past 20 days is 2.56% for REPL’s stock, with a -22.46% simple moving average for the past 200 days.
Analysts’ Opinion of REPL
Many brokerage firms have already submitted their reports for REPL stocks, with ROTH MKM repeating the rating for REPL by listing it as a “Buy.” The predicted price for REPL in the upcoming period, according to ROTH MKM is $17 based on the research report published on August 28, 2024 of the previous year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see REPL reach a price target of $44. The rating they have provided for REPL stocks is “Overweight” according to the report published on April 17th, 2023.
Piper Sandler gave a rating of “Overweight” to REPL, setting the target price at $52 in the report published on November 19th of the previous year.
REPL Trading at -20.29% from the 50-Day Moving Average
After a stumble in the market that brought REPL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -48.44% of loss for the given period.
Volatility was left at 9.02%, however, over the last 30 days, the volatility rate increased by 8.46%, as shares sank -18.99% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -37.66% lower at present.
During the last 5 trading sessions, REPL rose by +19.25%, which changed the moving average for the period of 200-days by +4.72% in comparison to the 20-day moving average, which settled at $8.55. In addition, Replimune Group Inc saw -27.62% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at REPL starting from Patel Sushil, who sale 10,000 shares at the price of $12.42 back on Dec 16 ’24. After this action, Patel Sushil now owns 202,014 shares of Replimune Group Inc, valued at $124,200 using the latest closing price.
Sushil Patel, the Chief Strategy Officer of Replimune Group Inc, proposed sale 15,000 shares at $12.57 during a trade that took place back on Dec 16 ’24, which means that Sushil Patel is holding shares at $188,550 based on the most recent closing price.
Stock Fundamentals for REPL
Current profitability levels for the company are sitting at:
- -59.64 for the present operating margin
- 0.66 for the gross margin
The net margin for Replimune Group Inc stands at -56.47. The total capital return value is set at -0.43. Equity return is now at value -50.50, with -40.16 for asset returns.
Based on Replimune Group Inc (REPL), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -6.14. The debt to equity ratio resting at 0.06. The interest coverage ratio of the stock is -30.68.
Currently, EBITDA for the company is -230.2 million with net debt to EBITDA at 0.65. When we switch over and look at the enterprise to sales, we see a ratio of 131.83. The receivables turnover for the company is 1.32for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.43.
Conclusion
In conclusion, Replimune Group Inc (REPL) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
